These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 23463626

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
    Lancet Oncol; 2013 Mar; 14(3):244-8. PubMed ID: 23414588
    [Abstract] [Full Text] [Related]

  • 3. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
    Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, Cortés J.
    Ann Oncol; 2014 Jun; 25(6):1116-21. PubMed ID: 24685829
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B.
    J Clin Oncol; 2009 Nov 01; 27(31):5278-86. PubMed ID: 19770385
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
    Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P.
    Ann Oncol; 2005 Nov 01; 16(11):1772-7. PubMed ID: 16150805
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators.
    Lancet Oncol; 2013 Jul 01; 14(8):741-8. PubMed ID: 23764181
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):275-80. PubMed ID: 18379783
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.
    BMC Cancer; 2007 Aug 08; 7():153. PubMed ID: 17686164
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
    Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU.
    Breast; 2013 Aug 08; 22(4):525-31. PubMed ID: 23352568
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
    Laakmann E, Witzel I, Fasching PA, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Zahm DM, Blohmer JU, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Loibl S.
    Breast Cancer Res; 2019 May 10; 21(1):60. PubMed ID: 31077239
    [Abstract] [Full Text] [Related]

  • 19. Central nervous system metastases in breast cancer patients administered trastuzumab.
    Duchnowska R, Szczylik C.
    Cancer Treat Rev; 2005 Jun 10; 31(4):312-8. PubMed ID: 15979804
    [Abstract] [Full Text] [Related]

  • 20. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S.
    Oncologist; 2008 Jun 10; 13(6):620-30. PubMed ID: 18586917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.